<DOC>
	<DOCNO>NCT01194193</DOCNO>
	<brief_summary>To investigate safety tolerability AZD8055 intermittent dose schedule give orally patient advance solid malignancy lymphomas . Two intermittent dose schedule explore increase dos maximum tolerate dose determined schedule .</brief_summary>
	<brief_title>Preliminary Anti-tumour Activity mTor Kinase Inhibitor Advanced Tumours</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Histological cytological confirmation advance solid malignant tumour lymphoma refactory standard therapy standard therapy exists , patient measurable nonmeasurable disease ( accord RECIST criterion ) WHO performance status 02 Evidence postmenopausal status negative urine/serum pregnancy test premenopausal female patient Patients severe laboratory abnormality haematology , liver renal function . Also treatment haemopoietic growth factor allow within two week first dose study drug . Any investigational agent study drug previous clinical study within 30 day , chemotherapy , immunotherapy anticancer agent within 3 week first dose study treatment Patients severe cardiac condition ischemia , impair ventricular function arrhythmia , evidence severe uncontrolled systemic current unstable uncompensated respiratory cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advanced solid tumour</keyword>
	<keyword>lymphoma</keyword>
	<keyword>dose escalation</keyword>
	<keyword>preliminary anti-tumour activity</keyword>
	<keyword>Tor kinase inhibitor</keyword>
	<keyword>oral administration</keyword>
	<keyword>intermittent dose</keyword>
</DOC>